Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) have received FDA approval for LEQEMBI (lecanemab-irmb), a groundbreaking treatment for Alzheimer's disease (AD), the most common type of dementia. LEQEMBI is the first approved therapy to demonstrate a reduction in disease progression and a significant slowdown of cognitive and functional decline in adults with AD. This progressive disease begins with mild memory loss and can eventually impair communication and responsiveness.

The FDA's approval of LEQEMBI has resulted in expanded Medicare coverage and the implementation of a user-friendly data submission process through a CMS-facilitated registry. This decision aims to facilitate reimbursement and improve access to LEQEMBI across various healthcare settings in the United States.

Eisai has taken the lead in the global development and regulatory submissions for LEQEMBI, while Eisai and Biogen are collaborating on the commercialization and promotion of the product. Eisai retains the final decision-making authority in this partnership.

$BIIB is currently trading at $288.83 in pre-market, up $3.84 (1.35%).

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)